305 related articles for article (PubMed ID: 29855362)
1. The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.
Tsuda Y; Ogura K; Shinoda Y; Kobayashi H; Tanaka S; Kawai A
BMC Cancer; 2018 May; 18(1):614. PubMed ID: 29855362
[TBL] [Abstract][Full Text] [Related]
2. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.
Nataraj V; Rastogi S; Khan SA; Sharma MC; Agarwala S; Vishnubhatla S; Bakhshi S
Clin Transl Oncol; 2016 Sep; 18(9):937-44. PubMed ID: 26742936
[TBL] [Abstract][Full Text] [Related]
3. Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.
Fukushima T; Ogura K; Akiyama T; Takeshita K; Kawai A
BMC Musculoskelet Disord; 2018 Aug; 19(1):297. PubMed ID: 30121085
[TBL] [Abstract][Full Text] [Related]
4. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Oncol; 2009 May; 20(5):955-60. PubMed ID: 19153123
[TBL] [Abstract][Full Text] [Related]
5. Survival and prognostic factors at time of diagnosis in high-grade appendicular osteosarcoma: a 21 year single institution evaluation from east Denmark.
Colding-Rasmussen T; Thorn AP; Horstmann P; Rechnitzer C; Hjalgrim LL; Krarup-Hansen A; Petersen MM
Acta Oncol; 2018 Mar; 57(3):420-425. PubMed ID: 28741397
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
7. Primary bone sarcomas in patients over 40 years of age: A retrospective study using data from the Bone Tumor Registry of Japan.
Nagano A; Ishimaru D; Nishimoto Y; Akiyama H; Kawai A
J Orthop Sci; 2017 Jul; 22(4):749-754. PubMed ID: 28412026
[TBL] [Abstract][Full Text] [Related]
8. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and prognostic factors of osteosarcoma of the jaws: a retrospective cohort study.
Lee RJ; Arshi A; Schwartz HC; Christensen RE
JAMA Otolaryngol Head Neck Surg; 2015 May; 141(5):470-7. PubMed ID: 25811167
[TBL] [Abstract][Full Text] [Related]
10. Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma.
Cates JMM
Am J Surg Pathol; 2018 Apr; 42(4):485-491. PubMed ID: 29200101
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
12. Statistics of bone sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan.
Ogura K; Higashi T; Kawai A
J Orthop Sci; 2017 Jan; 22(1):133-143. PubMed ID: 27847134
[TBL] [Abstract][Full Text] [Related]
13. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
[TBL] [Abstract][Full Text] [Related]
14. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
15. Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Salom M; Montalar J; Guasp M; Marco A; Castel V
J Pediatr Hematol Oncol; 2016 Apr; 38(3):176-81. PubMed ID: 26925713
[TBL] [Abstract][Full Text] [Related]
16. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
17. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
18. Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.
Prabowo Y; Setiawan I; Kamal AF; Kodrat E; Labib Zufar ML
Int J Surg Oncol; 2021; 2021():8843325. PubMed ID: 33996154
[TBL] [Abstract][Full Text] [Related]
19. Outcome of postradiation osteosarcoma does not correlate with chemotherapy response.
Lewis VO; Raymond K; Mirza AN; Lin P; Yasko AW
Clin Orthop Relat Res; 2006 Sep; 450():60-6. PubMed ID: 16906104
[TBL] [Abstract][Full Text] [Related]
20. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
